• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign.

作者信息

Ben-Tov Amir, Banon Tamar, Chodick Gabriel, Kariv Revital, Assa Amit, Gazit Sivan

机构信息

Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, Tel Aviv, Israel; Pediatric Gastroenterology Unit, Dana-Dwek Children's Hospital, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Maccabi Institute for Research & Innovation, Maccabi Healthcare Services, Tel Aviv, Israel.

出版信息

Gastroenterology. 2021 Nov;161(5):1715-1717.e1. doi: 10.1053/j.gastro.2021.06.076. Epub 2021 Jul 2.

DOI:10.1053/j.gastro.2021.06.076
PMID:34224740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8252826/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61ce/8252826/9fa85b649926/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61ce/8252826/9fa85b649926/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61ce/8252826/9fa85b649926/gr1_lrg.jpg

相似文献

1
BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign.BNT162b2信使核糖核酸新型冠状病毒肺炎疫苗在炎症性肠病患者中的有效性：大规模疫苗接种运动期间的初步真实世界数据
Gastroenterology. 2021 Nov;161(5):1715-1717.e1. doi: 10.1053/j.gastro.2021.06.076. Epub 2021 Jul 2.
2
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
3
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.在以色列全国范围内使用辉瑞-生物科技公司的 BNT162b2 mRNA COVID-19 疫苗进行疫苗接种运动，以预防感染、住院和死亡：一项回顾性监测研究。
Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22.
4
Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.BNT162b2 疫苗接种与孕妇感染 SARS-CoV-2 的关联。
JAMA. 2021 Aug 24;326(8):728-735. doi: 10.1001/jama.2021.11035.
5
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.BNT162b2疫苗接种者中SARS-CoV-2感染和新冠肺炎的早期感染率降低情况。
Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18.
6
Signals of hope: gauging the impact of a rapid national vaccination campaign.希望的信号：评估全国快速疫苗接种运动的影响。
Nat Rev Immunol. 2021 Apr;21(4):198-199. doi: 10.1038/s41577-021-00531-0.
7
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.BNT162b2和mRNA-1273新冠疫苗在卡塔尔针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔变种的有效性
Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 2.
8
COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States.新冠病毒疫苗对炎症性肠病患者安全有效：美国大型多机构研究网络的分析
Gastroenterology. 2021 Oct;161(4):1336-1339.e3. doi: 10.1053/j.gastro.2021.06.014. Epub 2021 Jun 15.
9
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.接种 BNT162b2 疫苗和加强针后，Delta 变异株 SARS-CoV-2 突破感染的病毒载量。
Nat Med. 2021 Dec;27(12):2108-2110. doi: 10.1038/s41591-021-01575-4. Epub 2021 Nov 2.
10
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.接种 BNT162b2 疫苗 13 至 24 天后对 SARS-CoV-2 感染有效性的评估。
JAMA Netw Open. 2021 Jun 1;4(6):e2115985. doi: 10.1001/jamanetworkopen.2021.15985.

引用本文的文献

1
Advancing equitable access to innovation in breast cancer.推进乳腺癌创新的公平可及性。
NPJ Breast Cancer. 2025 Jul 10;11(1):71. doi: 10.1038/s41523-025-00768-1.
2
Growing attention of immunogenicity among patients with autoimmune diseases post-SARS-CoV-2 vaccination: meta-analysis and systematic reviews of the current studies.SARS-CoV-2疫苗接种后自身免疫性疾病患者免疫原性受关注程度增加：当前研究的荟萃分析与系统评价
Ann Med. 2025 Dec;57(1):2478319. doi: 10.1080/07853890.2025.2478319. Epub 2025 Mar 26.
3
Sustainability: a multifaceted important aspect of cancer care.

本文引用的文献

1
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
2
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.炎症性肠病患者的新型冠状病毒2型疫苗接种：一项国际共识会议的建议
Gut. 2021 Apr;70(4):635-640. doi: 10.1136/gutjnl-2020-324000. Epub 2021 Jan 20.
3
Looking beyond COVID-19 vaccine phase 3 trials.
可持续性：癌症护理的一个多方面的重要层面。
BJC Rep. 2024 Mar 8;2(1):19. doi: 10.1038/s44276-023-00025-7.
4
Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study).我们反应过度了吗？大流行各阶段大量免疫介导炎症性疾病患者中新冠疾病与疫苗接种的见解（BELCOMID研究）
Vaccines (Basel). 2024 Oct 11;12(10):1157. doi: 10.3390/vaccines12101157.
5
Feasibility and Effectiveness of Vaccines for COVID-19: An Umbrella Review.2019冠状病毒病疫苗的可行性与有效性：一项系统综述。
Arch Acad Emerg Med. 2024 Sep 10;13(1):e6. doi: 10.22037/aaem.v12i1.2357. eCollection 2025.
6
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
7
Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving -TNF therapy: A systematic review and meta-analysis.新冠病毒疫苗在接受肿瘤坏死因子治疗的炎症性肠病患者中的疗效：一项系统评价和荟萃分析。
Heliyon. 2023 Sep 5;9(9):e19609. doi: 10.1016/j.heliyon.2023.e19609. eCollection 2023 Sep.
8
BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign.BNT162b2 mRNA COVID-19 疫苗在乳糜泻自身免疫患者中的有效性：大规模疫苗接种运动的真实世界数据。
Viruses. 2023 Sep 21;15(9):1968. doi: 10.3390/v15091968.
9
SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis.炎症性肠病患者新冠疫苗接种后出现的新冠病毒突破性感染：一项系统评价与荟萃分析
Therap Adv Gastroenterol. 2023 Jul 15;16:17562848231174295. doi: 10.1177/17562848231174295. eCollection 2023.
10
Effects of SARS-CoV-2 vaccine (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study.新型冠状病毒疫苗（Vero 细胞）对中国炎症性肠病患者疾病活动的影响：一项多中心研究。
Int J Colorectal Dis. 2023 Feb 9;38(1):31. doi: 10.1007/s00384-023-04315-x.
展望 COVID-19 疫苗 III 期临床试验之外。
Nat Med. 2021 Feb;27(2):205-211. doi: 10.1038/s41591-021-01230-y. Epub 2021 Jan 19.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
[ESTABLISHING A REGISTRY FOR INFLAMMATORY BOWEL DISEASE PATIENTS IN MACCABI HEALTHCARE SERVICES - JOINT PROJECT BETWEEN HOSPITALS, EPI-IIRN GROUP AND COMMUNITY MEDICINE].[在麦卡比医疗服务公司建立炎症性肠病患者登记处——医院、EPI-IIRN 集团与社区医学的联合项目]
Harefuah. 2018 Oct;157(10):655-659.